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Abstract: Invasive aspergillosis is a life-threatening fungal infection predominately affecting 
immunocompromised individuals. The incidence of inpatient-treated aspergillosis cases 
in the US is estimated to be between 3.02 and 3.80 per 10,000 hospitalized patients. The 
estimated difference in hospital costs of patients with an aspergillosis infection is US$36,867 
to US$59,356 higher than those of patients without the infection. Voriconazole is a synthetic, 
broad spectrum triazole antifungal agent, with FDA-approved indications for the treatment 
of invasive aspergillosis, esophageal candidiasis, candidemia in nonneutropenic patients, 
invasive candidiasis, and infections due to Scedosporium apiospermum and Fusarium species 
in patients refractory to or intolerant of other therapy. Eight cost-effectiveness analyses, one 
cost-minimization analysis, and one cost analysis were identified from a Medline search. The 
10 pharmacoeconomic analyses were conducted in six different countries comparing voricon-
azole to conventional amphotericin B, liposomal amphotericin B, itraconazole, and caspofungin. 
All the cost-effectiveness and cost-minimization analyses identified voriconazole as the most 
cost-effective therapy. The cost analysis demonstrated voriconazole cost-savings. While the 
acquisition costs of voriconazole are higher than those of conventional amphotericin B, the 
toxicity profile and rate of treatment success associated with voriconazole result in lower total 
treatment costs per successfully treated patient.
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Overview and management of invasive aspergillosis
Invasive aspergillosis is a life-threatening fungal infection predominately affecting 
immunocompromised individuals. The infection is most commonly caused by 
Aspergillus fumigatus, with Aspergillus flavus, Aspergillus niger, and Aspergillus 
terreus less often implicated.1 Profound and prolonged neutropenia is the most com-
mon risk factor associated with development of disease. As such, hematopoietic stem 
cell transplant (HSCT) recipients and patients receiving aggressive chemotherapy for 
hematologic cancers are at particular risk.2,3
Invasive aspergillosis most frequently begins in the lungs after inhalation of Aspergillus 
conidia. Initial, nonspecific manifestations include fever, cough, and dyspnea.4 Without 
treatment, invasive pulmonary aspergillosis is almost always fatal.1,4,5
Definitive diagnosis of invasive aspergillosis requires culture confirmation of 
Aspergillus species after biopsy of a sterile specimen. However, culture results lack 
sensitivity, may take as long as 4 weeks, and be confounded by contamination.1,4 
Prompt treatment is essential to improve survival. In the high-risk host, treatment is 
generally initiated based on signs and symptoms consistent with the disease. These may ClinicoEconomics and Outcomes Research 2009:1 36
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include fever despite the use of broad-spectrum antimicrobial 
agents, pulmonary infiltrates on CT scan (particularly with 
the presence of the halo or air-crescent sign), and/or detection 
of galactomannan antigen in the serum.1
Several antifungal agents are indicated for the treat-
ment of invasive aspergillosis, including amphotericin B 
and its lipid formulations, itraconazole, voriconazole and 
caspofungin. Voriconazole, however, is the drug of choice 
for the primary treatment of invasive aspergillosis.1 Voricon-
azole is initiated with a loading dose of 6 mg/kg intravenously 
(iv) every 12 hours for two doses and followed by 4 mg/kg 
every 12 hours. Parenteral administration is recommended 
in seriously ill patients, but clinically stable patients may be 
converted to oral tablets (with weight-based dosing rounded 
up to convenient pill sizes). A minimum of 6 to 12 weeks of 
therapy is required to adequately treat invasive pulmonary 
aspergillosis. Longer durations are necessary when prolonged 
periods of immune suppression are present and in cases where 
infected lesions are slow to resolve.1 Voriconazole levels 
have been correlated with antifungal efficacy and toxicity in 
several small studies.6,7 Though not yet routinely advocated, 
therapeutic drug monitoring is reasonable when drug toxicity 
or refractory fungal disease is suspected.4
The incidence of inpatient-treated aspergillosis cases 
in the US in the late 1990s was between 3.02 and 3.80 
per 10,000 hospital patients, representing over 10,000 
aspergillosis-related discharges from community hospitals.8,9 
The total US community hospital-related cost of aspergillosis 
in 1996 was estimated to be US$633.1 million.8 The esti-
mated difference in hospital costs of patients with aspergil-
losis in the late 1990s were US$36,867 to US$59,356 higher 
than those of patients without the infection.8,9 Using the 
US Bureau of Labor Statistics CPI Inflation Calculator, the 
equivalent 2009 amounts are US$48,110 to US$80,468.10 
Compared to patients with other invasive fungal infections 
such as candidiasis, histoplasmosis, and cryptococcosis, those 
with aspergillosis had the highest per-patient treatment costs 
(US$37,921/patient for inpatient care and US$34,871/patient 
for outpatient follow-up care).9 When adjusted to 2009 dollars 
the total cost to treat a patient with aspergillosis is US$94,991 
which is consistent with 2003 estimates provided by Tong 
and colleagues.11
Although voriconazole is considered first-line therapy 
for the primary treatment of invasive aspergillosis, it does 
not have the lowest acquisition cost of the FDA-approved 
treatments of invasive aspergillosis. Therefore the purpose 
of this article is to review the pharmacoeconomic studies 
that included voriconazole for the treatment of invasive 
aspergillosis. An overview of voriconazole is provided as 
background information.
Overview of voriconazole
Voriconazole is a synthetic, broad spectrum triazole antifungal 
agent that inhibits fungal cytochrome p450-dependent 
enzyme lanosterol 14-α-demethylase, ultimately decreasing 
the biosynthesis of ergosterol, an essential component of the 
fungal cell membrane. Voriconazole is FDA-approved for the 
treatment of invasive aspergillosis, esophageal candidiasis, 
candidemia in nonneutropenic patients, invasive candidiasis 
and infections due to Scedosporium apiospermum and 
Fusarium species in patients refractory to or intolerant of 
other therapy.12
Voriconazole is available as both oral and parenteral 
formulations. The oral tablet has a bioavailability 
exceeding 90%, which permits switching between formu-
lations when clinically appropriate. The kinetics of vori-
conazole are nonlinear, dose-dependent, and exhibit a high 
degree of inter-patient variability. It is metabolized by the 
P450 (CYP) enzymes CYP2C19, CYP2C9, and CYP3A4 to 
inactive metabolites. Its metabolism is saturable; increasing 
doses of voriconazole result in disproportional increases in 
drug exposure.13
Voriconazole is generally well tolerated. The most com-
monly reported adverse reactions, occurring in at least 5% 
of patients, include visual disturbances, elevated hepatic 
enzymes, fever, rash, nausea and vomiting.12,14,15 Visual and 
auditory hallucinations have also been occasionally reported 
in patients receiving voriconazole.12,15 Plasma voriconazole 
levels exceeding 5.5 µg/mL have been linked to higher 
incidences of neurologic events, visual disturbance and 
hepatotoxicity.6,7
Voriconazole has numerous drug-drug interactions, which 
may limit its usefulness in certain populations. Voriconazole 
is both a substrate and inhibitor of P450 (CYP) enzymes 
CYP2C19, CYP2C9, and CYP3A4.12,14,15
Voriconazole is available for IV use as a 200 mg 
powder for reconstitution and for oral use as 200 mg and 
50 mg tablets and a 200 mg/5 mL powder for suspension.12 
Average wholesale prices are US$121.63 per 200 mg iv vial, 
US$10.33 per 50 mg tablet, and US$41.33 per 200 mg 
tablet.16
Clinical outcomes
Historically, invasive aspergillosis-associated mortality 
rates have ranged from 60% to 90%, with central nervous 
system or disseminated infection or disease in HSCT patients ClinicoEconomics and Outcomes Research 2009:1 37
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conferring graver prognoses.17–20 Changes in transplantation 
practices, diagnostic procedures, and the extensive use of 
voriconazole have been credited with significant reductions 
in mortality rates.17,21
In 2002, Herbrecht and colleagues published the pivotal 
Global Comparative Aspergillosis (GCA) study sponsored 
by Pfizer.22 The investigators compared the efficacy and 
safety of voriconazole and conventional amphotericin B 
desoxycholate (CAB) for the primary treatment of inva-
sive aspergillosis in immunocompromised patients. This 
prospective, randomized trial involved 277 patients (n = 144, 
voriconazole; n = 133, CAB) aged 12 years or greater with 
definite or probable aspergillosis. Most had an underlying 
diagnosis of allogeneic HSCT or hematologic cancer and 
nearly half were neutropenic. The most common site of 
infection was the lungs.22
Voriconazole was dosed at 6 mg/kg iv every 12 hours × 2 
doses, then 4 mg/kg iv twice daily for at least 7 days, at 
which time it could be switched to oral administration of 
200 mg twice daily. CAB was dosed at 1.0 to 1.5 mg/kg iv 
daily. Other licensed therapy was permitted in the case of 
therapeutic failure or drug intolerance, which occurred in 
52 patients in the voriconazole and 107 patients in the CAB 
groups. The planned duration of therapy was 12 weeks.22
At week 12, voriconazole was associated with 
significantly improved response rates and survival and 
fewer adverse reactions than CAB. Successful response, 
defined as clinical improvement or resolution and at least 
50% improvement of radiologic findings, was achieved 
by 52.8% of patients receiving voriconazole and 31.6% 
of patients receiving CAB (absolute difference 21.2%; 
95% CI 10.4% to 32.9%). The survival rate was 70.8% in 
the voriconazole group versus 57.9% in the CAB group 
(HR 0.59; 95% CI 0.40 to 0.88). Renal impairment and 
infusion-related fevers and chills were more common in 
patients receiving CAB while voriconazole-treated patients 
were more likely to experience visual disturbances and 
dermatologic reactions.22
Based on the results of this trial, voriconazole replaced 
amphotericin B as first-line therapy for the treatment of 
invasive aspergillosis. A recent observational study using 
data compiled by the multicenter Prospective Antifungal 
Therapy (PATH) Alliance registry demonstrated mortality 
rates consistent with those reported by the Herbrecht trial.21 
In this study, the epidemiology and outcomes of 144 HSCT 
patients with invasive aspergillosis were examined. 
Eighty-five percent of these patients received treatment with 
voriconazole, 47% in combination with at least one other 
antifungal agent. Six- and 12-week mortality rates were 
21.5% and 35.5%, respectively.21
Economic outcomes
A Medline search using the terms “cost analysis” or 
“pharmacoeconomic analysis” plus “aspergillosis” plus 
“voriconazole” was serially repeated, substituting voricon-
azole with caspofungin, amphotericin B, and itraconazole. 
Studies were limited to those published in the English lan-
guage that compared both the costs and outcomes of invasive 
aspergillosis therapy and included a voriconazole arm. Ten 
publications met the inclusion criteria. These articles are 
summarized in Tables 1 to 5. These ten studies are compared 
globally by the type of analysis, methods used to estimate 
the cost and outcomes, results, transparency, and other 
methodological issues.
The 10 pharmacoeconomic analyses were conducted in 
six different countries as indicated in Table 1. Voriconazole 
was compared to CAB,23–30 liposomal amphotericin B 
(L-AMB),31 itraconazole,24 and caspofungin.32 Generally 
speaking all of the studies used the appropriate procedures 
for conducting pharmacoeconomic analyses with regard 
to their research question, modeling procedures, data 
sources, resource valuation, transparency, discounting, use 
of sensitivity analyses, and use of incremental analyses.33 
Any exceptions to these standards are noted in this section. 
Overall, the 10 studies had well-defined research questions, 
and they were transparent indicating that the data sources 
and methods for calculating expected costs and outcomes 
were obvious.
Eight of the studies were cost-effectiveness analyses 
(CEA),23–29,31 one was a cost-minimization analysis (CMA),32 
and one was a cost analysis (CA).30 No cost-utility analyses 
of voriconazole were identified, which is not surprising given 
the limited treatment period and the overall poor health con-
dition of people with invasive aspergillosis.
Eight of the voriconazole pharmacoeconomic studies 
used a decision analytic model such as a decision tree or 
Markov Model to estimate the expected costs and outcomes 
of therapy.23–29,31 One of the studies calculated the costs 
and outcomes from actual clinical observations and used 
a decision tree to calculate the weighted average cost and 
outcomes.23
The three outcomes reported in the studies were 
successful response at 12 weeks, survival at 12 weeks, and 
mean survival time. Tables 2, 3, and 4 present the results 
according to each of these outcomes, respectively. Since the 
studies were conducted in different countries with different ClinicoEconomics and Outcomes Research 2009:1 38
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healthcare systems and different currencies, no attempt was 
made to combine the results. All cost-effectiveness analyses 
or cost-minimization analyses identified voriconazole treat-
ment arms as the most cost-effective. This is not unexpected 
given the number of studies that used the results from GCA 
study as the primary source for outcomes data. However, the 
analyses that used multiple studies as the primary source for 
outcomes data reported similar results.31,32
None of the studies discounted costs or outcomes. This 
is appropriate for all of the studies that used the first two 
outcome measures since the study periods were less than 
12 months. Three studies reported mean survival times. Given 
that some of the costs and outcomes in these studies occurred 
outside the 12-month window, they should have been 
discounted. Most likely this is not a major issue given that 
the average life expectancy of the people included in these 
analyses ranged from less than 12 months to 3 years.24,28,31 
These three studies are described in greater detail below.
Jansen and colleagues used the results of the GCA study22 
as the basis of their decision tree which estimated 12 week 
cost and outcomes in a Dutch population.24 In the model, 
patients were treated initially with voriconazole, CAB, or 
itraconazole and were switched to other licensed antifungal 
agents in the case of severe toxicity or treatment failure. 
Since itraconazole was not included in the GCA study, 
they used other literature and expert opinion to identify 
resource use and probabilities of response and toxicities in 
the itraconazole arm. A Markov Model was then used to 
simulate the lifetime costs and outcomes of voriconazole, 
itraconazole, and amphotericin B as first-line treatments for 
invasive aspergillosis. Patients treated successfully at the 
end of 12 weeks remained in the “success” state until they 
died (an assumption of no relapses). Patients not successfully 
treated at the end of 12 weeks entered the Markov process in 
the “failure” state and remained there until they transitioned 
to the “success” or “death” states. Patients were transitioned 
from state to state on a weekly cycle based on probabilities 
derived from the GCA study. The mean survival times in this 
model were 174 weeks, 150.4 weeks, and 116.1 weeks for 
the voriconazole, itraconazole, and CAB groups respectively 
(see Table 4).24
Jansen and colleagues conducted a similar study for a 
German population. They used a decision tree and Markov 
model to simulate the 12 week and lifetime costs and out-
comes of voriconazole and amphotericin B as first-line 
treatments for invasive aspergillosis.28 The mean survival 
times in this model were 174 weeks and 116.1 weeks for the 
voriconazole and CAB groups respectively (see Table 4).28
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Ament and colleagues created a model to compare 
voriconazole and L-AMB as first-line therapy. After severe 
toxicity or treatment failure, a patient in the model could 
be switched to any combination of other antifungal agents.31 
Seven different treatment combinations were compared in the 
final analysis: 1) voriconazole as first-line and L-AMB plus 
caspofungin as second-line therapy, 2) voriconazole as first-
line and caspofungin as second-line therapy, 3) voriconazole 
as first-line and CAB as second-line therapy, 4) voriconazole 
as first-line and L-AMB as second-line therapy, 5) L-AMB 
as first-line and voriconazole plus caspofungin as second-
line therapy, 6) L-AMB as first-line and voriconazole as 
second-line therapy, 7) L-AMB as first-line and caspofungin 
as second-line therapy. Probabilities used in the model were 
derived from multiple published studies. The mean survival 
times ranged from 1.109 to 1.307 years as summarized in 
Table 4.31
Four additional studies are described in greater detail to 
highlight their unique designs or contributions to the litera-
ture. Dominguez-Gil and colleagues conducted a cost mini-
mization analysis comparing voriconazole and caspofungin 
from a hospital perspective. Based on probabilities obtained 
from multiple published studies, the authors determined or 
assumed that both agents would have equal efficacy. The 
average cost of the voriconazole-treated group was  1,132 
lower than the caspofungin-treated group (see Table 5).32
Green and colleagues used a subset of patients from the 
GCA study that had thoracic computed tomographic (CT) 
scans at baseline to look at the cost-effectiveness of voricon-
azole compared to CAB.29 They divided the patients into two 
groups, those with and without a halo sign on the CT scan at 
baseline. The probabilities of toxicity and success in these 
patients were used to model the expected cost and outcomes 
in each group. The probability of survival at 12 weeks was 
the outcome measure. Both groups had similar costs, but the 
group with the halo sign had better survival rates than the 
group without the sign. This resulted in lower costs per out-
come in the group with the halo sign. Voriconazole was the 
most cost-effective agent in both groups (see Table 3).29
Wingard and colleagues conducted a cost analysis using 
data from the GCA study as the primary source of out-
comes data.30 Consideration was not given to any outcome 
measure, but the patients were subdivided into survivors 
and nonsurvivors. The group treated with voriconazole had 
lower treatment costs compared to the group treated with 
CAB resulting in US$16,758 savings in the survivor group. 
Conversely, the non-survivor group treated with CAB had 
savings of US$10,176 compared to the voriconazole group. 
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When all patients were considered together, patients treated 
with voriconazole had a US$4,997 savings compared to 
patients treated with CAB (see Table 5).30
Overall the results of all of the analyses were robust to 
the assumptions made during the modeling process. This 
means that the results of the analysis did not change when 
the key assumptions of the models were tested in sensitiv-
ity analyses (ie, varied from high to low values). However 
the results of four studies were sensitive to drastic changes 
in either costs, the weight of the patient used to estimate 
the medication dose, or the renal toxicity of CAB.23,27,31,32 
In the model used by Roststein and colleagues, patients 
were switched to L-AMB due to toxicity or treatment 
failure of voriconazole or CAB. If the cost of L-AMB 
was cut in half, then the CAB arm became more cost-
effective.23 In the model used by Garbino and colleagues, 
when the renal toxicity of amphotericin B was assumed 
to be less than 7%, then the CAB arm became more cost-
effective.27 The results published by Dominguez-Gil and 
colleagues were robust as long as the patients weight was 
less than 102 kg.32
Testing the conclusions of the pharmacoeconomic 
analyses with sensitivity analyses described above is one 
way to validate study results. In an attempt to further validate 
the results of a similar pharmacoeconomic analysis that 
has not been published, Van Campenhout and colleagues 
compared the results of the model to actual data collected 
from 116 patients in 13 different hematology–oncology 
intensive care settings in Belgium.34 The clinical response 
rate at 12 weeks was similar (53% from the model, 50% from 
the observational study). However the model underestimated 
the mortality rates at 84 days (29% vs 42%) and slightly 
overestimated the per-patient cost of hospitalizations 
( 21,298 vs  19,674).34
Two of the studies included in this review accounted for 
the cost of the galactomannan assays,24,28 but none included 
the costs of voriconazole levels. The galactomannan assay 
is a diagnostic test, therefore the cost of this test would 
be incurred regardless of the therapy selected. In other 
words, including the cost of this diagnostic test in any of 
the pharmacoeconomic analyses would not change the 
results. The current treatment guidelines do not address 
the routine use of voriconazole levels. An observational 
study by Pascual and colleagues evaluated the impact of 
measuring voriconazole blood levels.6 Patient with troughs 
less than 1 mg/L had worse outcomes compared to those 
with troughs between 1 and 5.5 mg/L, while patients 
with troughs higher than 5.5 mg/L had more toxicity.6 ClinicoEconomics and Outcomes Research 2009:1 42
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Table 5 Summary of cost minimization and cost analysis studies
Author Year Country Currency Comparators Analysis 
Type
Expected cost 
per patient
Cost difference Comments
Dominguez-Gil32 2007 Spain 2006 € voriconazole 
caspofungin
CMA 6,042 
7,174
-1,132.18 Cost-effective agent 
Dominated
wingard30 2007 US 2005 US$ voriconazole (all patients) CA 78,860 -4,997.00 Cost savings
CAB (all patients) 83,857
voriconazole (survivors) 79,913 -16,758.00 Cost savings
CAB (survivors) 96,671
voriconazole  
(non-survivors)
76,326 10,176.00 No cost savings
CAB (non-survivors) 66,150
Abbreviations: CAB, conventional amphotericin B desoxycholate; CA, cost analysis; CMA, cost-minimization analysis.
The median number of troughs drawn per patient was 4.5 
with the first drawn a median of 5 days after therapy and 
every 7 days thereafter. The cost of this test is difficult to 
identify; however, the Centers for Medicare and Medicaid 
Services (CMS) 2009 Clinical Diagnostic Laboratory Fee 
Schedule limits for other drug assays ranges from US$17.40 
to US$27.00.35 Thus if one assumes the cost to a payer 
would be the upper end of this limit (US$27 per trough) 
with five troughs per patient, then an additional US$135 
would be added to the cost of therapy. When the cost of 
the assay is added to the expected costs calculated in each 
of the US-based pharmacoeconomic studies in this review, 
the results do not change. Voriconazole remains the most 
cost-effective therapy.
Conclusions
Amphotericin B and its lipid formulations, itraconazole, vori-
conazole and caspofungin, are all indicated for the primary 
treatment of invasive aspergillosis; however, voriconazole 
is preferred.1 The GCA study by Herbrecht and colleagues 
provided the clinical evidence to support voriconazole’s 
clinical role.22 This publication also served as the basis for 
multiple pharmacoeconomic analyses which demonstrated 
that voriconazole is cost-effective in the primary treatment 
of invasive aspergillosis.
Of the agents indicated for the primary treatment of 
invasive aspergillosis, the US average wholesale price 
of L-AMB is the highest followed by caspofungin, 
voriconazole, itraconazole, and CAB.16 While the 
acquisition costs of voriconazole are higher than those 
of conventional amphotericin B, the toxicity profile and 
treatment success rate associated with voriconazole result 
in lower total treatment costs per successfully treated 
patient.23–30
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